Ipsen Stock News
€149.10
0.68%
Paris, Sep 24, 05:35 pm CEST.
Closed.
Industry
Ipsen Stock News
Stock fell sharply after the U.S. Food and Drug Administration approved a generic competitor to its flagship Somatuline hormone drug earlier than expected.
The French drugmaker is considering building a production site in the U.S., joining other European companies looking across the pond when planning new investments.
IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2025
The drugmaker sees gaps in its portfolio and has the financial means to fill them, its chief business officer said, signaling more deals are to come after this week's pair of acquisitions.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
